B+
Bull case
20%
Probability
Target price
$1.60
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
CMPX
Compass TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
COMPANION-002 met its response-rate endpoint and showed a progression-free-survival benefit. If further FDA engagement permits a filing without a new survival trial, substantial upside remains possible; that outcome is not established.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
A longer development path could increase cash burn or financing needs; the June runway projection may change. [#PR-EARNINGS-2026-08-06] https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm
Momentum
35
Value
58
Sentiment
69
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.82 · Bull $1.60 · Bear $0.45Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $5.50
Why
Momentum35 · Δ7d -
Value58 · Δ7d -0.5
Sentiment69 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • A longer development path could increase cash burn or financing needs; the June runway projection may change. [#PR-EARNINGS-2026-08-06] https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm
- • COMPANION-002 overall survival was not statistically significant despite response-rate and progression-free-survival benefits. [#PR-2026-09-22] https://www.sec.gov/Archives/edgar/data/1738021/000117184326006162/exh_991.htm
- • Overall survival did not reach statistical significance, and the FDA recommended another trial before submission.
Catalyst clock
2026-10-31
COMPANION-002 data presentation at ESMO
Lead driver: Sentiment · See AI snapshot
Momentum
35
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
47% active weight
Current posture
7d trendFlat
Δ7d
-0.5
Δ21d
+16.5
Sentiment
69
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 34.9 / Value 57.5 / Sentiment 69.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.82
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.45
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$134.56M
Beta
1.27
Shares Out
180.09M
P/E (TTM) · Derived
-1.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.42
Rev YoY
-100.0%
EPS YoY
-6.3%
Gross Margin
-94.6%
Op Margin
-7273.4%
Net Debt
-$199.08M
Current Ratio
11.22
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data